6篇
您的检索式：作者名="Michael Mix"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage Ⅲ nonsmall cell lung cancer显示文摘AIM: To prospectively determine the safety and tolerability of oral L-selenomethionine(SLM) with concurrent chemoradiation(CCRT) for Stage Ⅲ non-small cell lung cancer(NSCLC) and estimate if the incidence and/or severity of adverse events could be reduced by its use.METHODS: Sixteen patients with stage Ⅲ NSCLC were accrued to this single arm, phase Ⅱ study. CCRT consisted of radiation given at 2 Gy per fraction for 30-33 fractions, 5 d per week with concurrent weekly Ⅳ paclitaxel 50 mg/m2 followed by carboplatin dosed at an area under the time-concentration curve of 2. SLM was dosed in a loading phase at 4800 μg twice daily for one week prior to CCRT followed by once daily dosing during treatment. RESULTS: No selenium-related toxicity was observed. Analysis revealed grade 3 or higher esophagitis in 3 of 16 patients(19%), pneumonitis in 0, leukopenia in 2(12.5%), and anemia in 1(6%); the latter two were significantly reduced when compared to the protocolstated expected rate of 35%(P = 0.045 for leukopenia, and P < 0.01 for anemia). Median overall survival was 14.9 mo and median failure-free survival was 9 mo(95%CI: 3.3-21.5).CONCLUSION: There may be some protective benefit of selenium in the setting of CCRT for inoperable NSCLC. The data suggests decreased rates of myelosuppression when compared to similarly-treated historical and contemporary controls. Further evaluation of selenium in this setting may be warranted. | Michael Mix Nithya Ramnath Jorge Gomez Charles de Groot Saju Rajan Shiva Dibaj Wei Tan Youcef Rustum Michael B Jameson Anurag K Singh | 2015 | World Journal of Clinical Oncology2015，6，5： | 4 |
| 2 | Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis显示文摘 | Mix Kimberlee S K S Sporn Michael B M B Brinckerhoff Constance E C E etal | 2004 | Clin OrthopRelat Res2004，427，1： | 1 |
| 3 | Chronic Inflammation and Impaired Coronary Vasoreactivity in Patients With Coronary Risk Factors显示文摘 | Thomas H. Schindler Egbert U. Nitzsche Manfred Olschewski Nobuhisa Magosaki Michael Mix John O. Prior Alvaro D. Facta Ulrich Solzbach Hanjoerg Just Heinrich R. Schelbert | 2004 | Circulation2004，，9： | 1 |
| 4 | Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis显示文摘 | Mix Kimberlee S K S Sporn Michael B M B Brinckerhoff Constance E C E | | 0，，427： | 1 |
| 5 | Eligibility and safety of the first interferon‐free therapy against hepatitis C in a real‐world setting显示文摘 | Christoph H?ner zu Siederdissen Benjamin Maasoumy Katja Deterding Kerstin Port Lisa Sollik Carola Mix Janina Kirschner Janet Cornberg Michael P. Manns Heiner Wedemeyer Markus Cornberg | 2015 | Liver Int2015，，7： | 1 |
| 6 | Randomized phase Ⅱ trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck显示文摘AIM: To investigate whether selenomethionine(SLM) reduces mucositis incidence in patients with head and neck squamous cell cancer(HNSCC) undergoing concurrent chemoradiation(CRT).METHODS: In this multi-institutional, randomized, double-blind phase Ⅱ trial, patients with Stage Ⅲ or Ⅳ HNSCC received SLM 3600 μg/m2 or placebo twice daily for 7 d prior to CRT, once daily during CRT, and daily for 3 wk following CRT. CRT consisted of 70 Gy at 2 Gy per fraction with cisplatin 100 mg/m2 Ⅳ on days 1, 22, and 43. RESULTS: Eighteen patients were randomized, 10 received SLM, and there were no differences in baseline factors. There was no difference in mucositis or patientreported side effects between groups. There was no difference in overall or relapse-free survival at 12 mo.CONCLUSION: Addition of SLM to CRT for HNSCC was well-tolerated but did not lower the incidence of severe mucositis or improve quality of life or survival outcomes. | Michael Mix Anurag K Singh Michael Tills Shiva Dibaj Adrienne Groman Wainwright Jaggernauth Youcef Rustum Michael B Jameson | 2015 | World Journal of Clinical Oncology2015，6，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员